The FDA has released a draft guidance covering the development, trial design, testing and approval pathways for neurodegenerative disease gene therapies. The guidance, which applies to human gene treatments for both pediatric and adult populations, underlines the importance of communicating with the FDA before submitting an investigational new drug application.
FDA offers guidance on neurodegenerative gene therapies
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.